AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$FATE

FATE THERAPEUTICS INC

Price · $FATEvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $FATE in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $FATE in the last 30 days.

Top stories · $FATEMore →
MAY 12·GlobeNewswireHigh

Fate Therapeutics Showcases FT819 Clinical Activity in SLE

Fate Therapeutics showcased positive clinical data for its off-the-shelf CAR T-cell programs FT819, FT839, and FT836 at the 2026 ASGCT Annual Meeting. FT819 demonstrated efficacy in systemic lupus erythematosus (SLE) patients without conditioning chemotherapy, achieving lupus low disease activity and B cell remodeling. Preclinical data for FT839 and FT836 also showed promising results for autoimmune diseases and cancer, respectively, highlighting the potential for less intensive or no conditioning chemotherapy in cellular immunotherapies.

MAY 8·Stock Titan

Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k shares

Fate Therapeutics officer Cindy Tahl exercised stock options to acquire 166,664 shares of FATE common stock on May 6, 2026. This transaction involved exercising options at $1.05 and $1.32 per share, and she now directly holds 609,301 shares. The exercises were compensation-related and no open-market sales were reported.

APR 9·GlobeNewswire

Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

Fate Therapeutics, Inc. announced its management will participate in five investor conferences during the second quarter of 2026, including virtual and in-person events like the Needham, Bank of America, H.C. Wainwright, Jeffries, and Goldman Sachs healthcare conferences. The company, a clinical-stage biopharmaceutical firm, focuses on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. Webcasts of presentations, if available, will be on their website.

News on $FATE

All news →